Interesting detail on getting PRV $$$ - costs to LMNL Looks like LMNL will continue to carry Plasma division costs until the PRV is sold which could be some or many months. What a disaster deal management has made. How are they even still working? There is a much bigger picture happening here. Thomvest is positioning everything as a failure to justify taking it private. Just wait.
The Share Purchase Agreement provides for payment of USD 5 million payable upon closing of the sale of the shares of PBP (the “First Closing”) and provides for the right for Liminal BioSciences to receive from PBT an amount equal to seventy percent (70%) of the net proceeds obtained from the sale of a PRV prior the closing of the sale of the shares of PBT (the “Second Closing”). Upon closing of the two transactions, Kedrion would assume all development, manufacturing and commercialization activities and operating costs for Ryplazim®.